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Background: MiR-221 and miR-222 (miR-221/222), upregulated in gliomas, can regulate glioma cell cycle
progression and apoptosis, respectively. However, the association of miR-221/222 with glioma cell invasion and
survival remains unknown.
Methods: Invasion capability of miR-221/222 was detected by mutiple analyses, including diffusion tensor imaging
(DTI), transwell, wound healing and nude mouse tumor xenograft model assay. Further, the target of miR-221/222
was determined by luciferase reporter, western blot and gene rescue assay. The association of miR-221/222 with
outcome was examined in fifty glioma patients.
Results: MiR-221/222 expression was significantly increased in high-grade gliomas compared with low-grade
gliomas, and positively correlated with the degree of glioma infiltration. Over-expression of miR-221/222 increased
cell invasion, whereas knockdown of miR-221/222 decreased cell invasion via modulating the levels of the target,
TIMP3. Introduction of a TIMP3 cDNA lacking 3’ UTR abrogated miR-221/222-induced cell invasion. In addition,
knockdown of miR-221/222 increased TIMP3 expression and considerably inhibited tumor growth in a xenograft
model. Finally, the increased level of miR-221/222 expression in high-grade gliomas confers poorer overall survival.
Conclusions: The present data indicate that miR-221 and miR-222 directly regulate cell invasion by targeting TIMP3
and act as prognostic factors for glioma patients.
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Glioblastoma multiforme (GBM) is the most frequent
malignant primary brain tumor in adults. The hallmark
of GBM is the widespread diffuse invasion of tumor cells
into brain tissues. Owing to the aggressive infiltration
into the surrounding normal brain, current therapies fail
to control GBM [1,2]. With standard treatment, GBM
patients have a median survival of 15.6 months, despite
of surgery, radiation therapy and chemotherapy [3].
Thus, there is an urgent need to develop novel* Correspondence: kang97061@yahoo.com
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reproduction in any medium, provided the ortherapeutic approaches that focus on controlling the in-
vasion of this malignancy.
MicroRNAs (miRNAs), a recently identified class of
endogenous, small (~22 nt), non-protein coding, single-
stranded RNA molecules, negatively regulate protein-
coding genes by base-pair matching with the 3’ UTRs of
mRNAs. MiRNAs are dysregulated in tumors and func-
tion as oncogenic miRNAs or as tumor suppressor miR-
NAs [4]. Growing evidence has indicated important roles
for miRNAs in tumor invasion. MiR-21 is an important
oncogenic miRNA that promotes cell invasion by regu-
lating multiple genes, including PTEN, RECK and
MARCKS in several kinds of cancers, such as glioma,
ovarian epithelial carcinoma and prostate cancer [5-7].
In pancreatic cancer cells, miR-146a inhibits the invasive
capacity with concomitant down-regulation of EGFR and
the NF-kappaB regulatory kinase, interleukin 1 receptor-
associated kinase 1 (IRAK-1) [8]. In addition, in gliomaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhang et al. Journal of Translational Medicine 2012, 10:119 Page 2 of 11
http://www.translational-medicine.com/content/10/1/119cells, miR-7 binds to the EGFR 3’UTR and decreases cell
invasiveness by suppressing translation of EGFR [9].
Over-expression of miR-146b inhibits glioma cell inva-
sion by targeting matrix metalloproteinases (MMPs)
[10]. However, there is little direct evidence to show the
mechanism by which miR-221/222 controls glioma
invasion.
In the current study, we demonstrate that high levels
of miR-221/222 expression in gliomas confer highly ag-
gressive invasion and poorer overall survival. Further-
more, knockdown of miR-221/222 decreased invasion
capability, reduced tumor growth and up-regulated the
expression of the target, TIMP3, whereas ectopic expres-
sion of miR-221/222 exhibited the opposite effects.
These findings indicate that TIMP3 is a critical target of
miR-221 and miR-222 and that these two miRNAs could
be critical therapeutic targets and survival predictors in
glioma.
Materials and methods
Tissue samples and clinical data
All patients underwent complete or partial surgical re-
section at Tianjin Huanhu Hospital and Beijing Tiantan
Hospital. Fifty paraffin-embedded glioma specimens with
clinical data were collected from January 2006 to June
2006, including 14 grade I-II tumors, 18 grade III tumors
and 18 grade IV tumors. Twenty-two frozen glioma spe-
cimens, stored in liquid nitrogen, were collected from
October 2009 to May 2010, including 9 grade I-II
tumors, 6 grade III tumors and 7 grade IV tumors. Paraf-
fin-embedded glioma specimens were used for MiRNA
locked nucleic acid (LNA) in situ hybridization and
immunohistochemistry, and frozen glioma specimen
were used for Real-time PCR. This study was approved
by the institutional review boards of the hospitals (the
Ethics Committees of Tianjin Medical University,
TMUhMEC 2009016) and written informed consent was
obtained from all patients. Patients were followed by
clinical and laboratory monitoring on a regular basis
starting at definitive diagnosis. Disease-specific survival
time was defined as the time from definitive diagnosis to
disease-specific death.
MR data acquisition
Patients were scanned with a 3.0 T clinical MR imaging
scanner (Magnetom Sonata; Siemens, Erlangen, Germany)
equipped with the standard head coil according to a stan-
dardized hospital brain tumor imaging protocol. The scans
used for this study included diffusion tensor imaging
(DTI) and axial contrast-enhanced T1-weighted spin-echo
scans. In low-grade gliomas, peritumoral edematous
regions were selected by T2 and FLAIR. In every patient,
we measure three times in peritumoral edematous differ-
ent regions with the volume of ROI (5 pixels). DTI datawere transferred to a workstation (Inspiron 8200; Dell,
Round Rock, TX, USA) for analysis. Data processing was
performed using DTIStudio (version 2.4; Johns Hopkins
University, Baltimore, MD, USA).
Cell culture and transfection
Human U251 and LN229 glioblastoma cells, were
obtained from the China Academia Sinica Cell Repository,
Shanghai, China. The cells were maintained in Dulbecco’s
modified Eagle’s medium (Gibco, Los Angeles, CA, USA)
supplemented with 10% fetal bovine serum (Gibco), and
were incubated at 37°C in a 5% CO2 atmosphere. Cell
transfection was performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Plasmids and oligonucleotides
2′-OMe-oligonucleotides were chemically synthesized and
purified by high-performance liquid chromatography (Gene
Pharma, Shanghai, China). The sequences are: 2'-OMe
-miR-221 (miR-221), 5'-AGCUACAUUGUCUGCUGGGU




GU-3'. Then As-miR-221 and/or As-miR-222 (200 pmol)
were transfected using Lipofectamine 2000 (Invitrogen).
Cells transfected with scrambled 2'-OMe oligonucleotides
(scramble) were used as control. Wild-type TIMP3 lacking
its 3′ UTR in pCDNA3 was provided by Dr. J.Q. Cheng
(Molecular Oncology, H. Lee Moffitt Cancer Center,
Tampa, FL, USA).
Real-time PCR
MiRNA expression was analyzed using a Hairpin-itTM
miRNA qPCR Quantitation Kit (GenePharma, Shanghai,
China) and a DNA Engine Opticon 2 Two-color Real-
time PCR Detection System (Bio-Rad, USA), according
to the manufacturer’s instructions. Cycle threshold (CT
value) was acquired using the software provided by the
manufacturer. U6 is used as the normalization gene in
Real-time PCR. The real-time PCR data were analyzed
using the ddCT method.
Transwell assay
Cells were detached and resuspended in serum-free
medium. Cells (1 × 105 cells/well) were then plated into
Matrigel coated invasion chambers (Becton Dickinson)
and allowed to invade for 24 hours. The remaining cells
in the chambers were removed by cotton swabs and the
invading cells on the lower surface of the chambers
were fixed with 70% ethanol and then stained with
hematoxylin. The number of invading cells was calcu-
lated by counting three different fields under a phase-
contrast microscope.
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Cells were optimized to ensure a homogeneous and viable
cell monolayer prior to wounding. Equal numbers of cells
were seeded into six-well culture plates. According to the
above methods, cells were transfected with As-miR-221/
222 or miR-221/222. When the cell confluence reached
about 90% at 48 h post-transfection, an artificial
homogenous wound was created on the monolayer with a
sterile plastic 100 μL micropipette tip. After wounding, the
debris was removed by washing the cells with serum-free
medium. Migration of cells into the wound was observed
after 36 h. Cells that migrated into the wounded area or
cells with extended protrusions from the border of the
wound were photographed. A total of three areas were
selected from each well at random, and three wells of each
group were quantified in each experiment.
Western blot
Parental and transfected cells were washed with pre-
chilled phosphate-buffered saline (PBS) three times. The
cells were then solubilized in 1% Nonidet P-40 lysis buf-
fer (20 mM Tris, pH 8.0, 137 mM NaCl, 1% Nonidet
P-40, 10% glycerol, 1 mM CaCl2, 1 mM MgCl2, 1 mM
phenylmethylsulfonyl fluoride, 1 mM sodium fluoride,
1 mM sodium orthovanadate, and a protease inhibitor
mixture). Total protein lysates were separated by SDS-
PAGE. The separated proteins were transferred to PVDF
membranes. Blots were incubated with MMP2, MMP9
and TIMP3 (Santa Cruz) primary antibodies, followed
by incubation with HRP-conjugated secondary antibody.
The specific protein was detected using a super signal
protein detection kit (Pierce). After washing with strip-
ping buffer, PVDF membranes were reprobed with anti-
body against β-actin.
ELISA assay
Twenty-four hours post-transfection, cell culture media
were collected and quantified for MMP2 and MMP9
levels using an MMP2 and MMP9-specific ELISA kit
(R&D Systems, Minneapolis, MN, USA), according to
the manufacturer’s protocol.
MiRNA locked nucleic acid (LNA) in situ hybridization and
immunohistochemistry
Using an antisense locked nucleic acid (LNA/DNA) modi-
fied oligonucleotide probe, in situ hybridization was per-
formed with fluorescence in situ hybridization kit
(CYBRDI, China). MiR-221 and miR-222-LNA oligonu-
cleotides with digoxigenin modification contained LNAs at
five locations (underlined): 5′-GAAACCCAGCAGACAAT
GTAGCT-3′ (miR-221); 5′-GAGACCCAGTAGCCAGAT
GTAGCT-3′ (miR-222). LNA-miR-221 uses DIG modifica-
tion and LNA-miR-222 uses BIO modification in 3' distal
end. Sections were deparaffinized and deproteinated, andthen prehybridized for 2 h in hybridization liquid in a hu-
midified chamber (50% formamide, 5 x SSC). The probes
were added to the sections and incubated overnight at 40°C
in a water bath. After washing 3 times, anti-digoxigenin-
rhodamine solution was added and incubated for 2 h at
room temperature in the dark. Nuclei were counterstained
with a DAPI karyotyping kit (Genmed, USA). After wash-
ing 3 times, sections were sealed and detected under a
fluorescence microscope. In immunohistochemistry assay,
sections were incubated with primary antibody (1:100 dilu-
tion) overnight at 4°C, then incubated with a biotinylated
secondary antibody (1:200 dilution) at room temperature
for 1 h, followed by incubation with ABC-peroxidase re-
agent for an additional 1 h. After washing with Tris-buffer,
the sections were stained with DAB (30 mg 3,3 diamino-
benzidine dissolved in 100 ml Tris-buffer containing 0.03%
H2O2) for 5 min, rinsed in water and counterstained with
hematoxylin. The antibodies used in this study were to
MMP2, MMP9 and TIMP3. The quantity and intensity
scores were calculated such that a final score of 0–1 indi-
cated negative expression (−), 2–3 indicated weak expres-
sion (+), 4–5 indicated moderate expression (++) and 6
indicated strong expression (+++).
Luciferase reporter assay
The pGL3-WT-TIMP3-3’UTR-Luc reporter was created
by the ligation of TIMP3 3’ UTR PCR products into the
XbaI site of the pGL3 control vector (Promega, USA).
For the reporter assay, cells were cultured in 96-well
plates and transfected with pGL3-TIMP3-3’UTR-Luc,
and As-miR-221 and/or As-miR-221. Following 48 h in-
cubation, luciferase activity was measured using a dual-
luciferase reporter system (Promega).
Nude mouse tumor xenograft model and treatment
U251 glioma cells were subcutaneously injected into 5-
week-old female nude mice (Cancer Institute of the
Chinese Academy of Medical Science). When the tumor
volume reached 50 mm3, the mice were randomly
divided into four groups (eight mice per group). Each
group was treated with 200 pmol scramble oligo, As-
miR-221/222 in 10 μl Lipofectamine, miR-221/222 or
PBS through local injection of the xenograft tumor at
multiple sites (3–4 injected sites). The treatment was
performed once every 3 days for 15 days. On day 28,
tumors were harvested, fixed embedded in paraffin. The
tumor volume was measured with a caliper twice a week,
using the formula: volume = length ×width2/2.
Statistical analysis
Descriptive statistics, including mean and±SE, along with
independent sample t-tests, and the Pearson correlation
were used to determine significant differences. Kaplan-
Meier analysis was employed to assess the survival rate of
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222. P< 0.05 was considered a significant difference.Results
Correlation of miR-221/222 expression levels and glioma
invasion
To evaluate tumor invasion in patients, we employed
MR DTI, which is an MRI technique that can indirectly
evaluate the integrity of the white matter by measuring
water diffusion and its directionality. As shown in Figure
1A, the fractional anisotropy (FA) map and the three-
dimensional reconstruction of the fibers surrounding the
glioma showed that GBM invaded and destroyed the cor-
ticospinal tract, while in grade II glioma the corticospinal
tract was pushed around the tumor. For quantitative
analysis of miR-221 and miR-222 in frozen tumor tissues
of 22 patients, we performed real-time PCR. MiR-221 ex-
pression was significantly increased in high-gradeFigure 1 DTI and expression of miR-221 and miR-222 in gliomas. (A) D
c and d: three-dimensional reconstruction of the fibers surrounding the glio
glioma tissues assayed by real-time PCR. (C) Correlation between FA values
Pearson correlation analysis.gliomas compared with low-grade gliomas, and a similar
trend for miR-222 was detected (Figure 1B). Recently,
FA values from peritumoral edematous regions have
been reported to be a quantitative index of brain inva-
sion by glioma cells and to be negatively correlated with
the degree of glioma infiltration [11]. The Pearson cor-
relation showed that a significant negative correlation
existed between FA values and miR-221 and miR-222 ex-
pression in these 22 gliomas (R = 0.755, P< 0.005 and
R= 0.612, P< 0.005, respectively) (Figure 1C). These
findings suggest that miR-221/222 may have an import-
ant role in glioma invasion.Critical role of miR-221/222 in glioma cell invasion
To further explore the role of miR-221/222 in cell inva-
sion, we performed gain-of-function and loss-of-function
analyses by over-expressing or suppressing miR-221/222
with As-miR-221/222 or miR-221/222, respectively.TI in glioma. a: contrast enhanced T1-weighted MRI; b: FA color map;
ma (yellow); e: HE stain. (B) MiR-221 and miR-222 expression in 22
and miR-221 and miR-222 expression in these 22 gliomas by the
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down of miR-221/222 significantly decreased cell inva-
sion potential compared with cells treated with
scrambled oligonucleotide, whereas over-expression ofFigure 2 MiR-221 and miR-222 play an important role in glioma cell i
miR-221/222, and transwell assays and wound healing assays were perform
MMP2 and MMP9 protein levels were detected by western blot assays. β-ac
also measured by ELISA assays. Error bars represent standard deviation and
compared with control group, ** P <0.01 compared with control group.miR-221/222 increased cell invasion (Figure 2A). Con-
sistent with the results of the transwell assay, in the
wound healing assay, repression of miR-221/222 signifi-
cantly inhibited cell migration, while over-expression ofnvasion. (A) and (B) Cells were transfected with As-miR-221/222 or
ed. (C) Cells were transfected with As-miR-221/222 or miR-221/222 and
tin protein was assayed as a control. MMP2 and MMP9 levels were
were obtained from three independent experiments. * P <0.05
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cells (Figure 2B). To further explore the proteins relevant
to invasion, the level of MMP2 and MMP9 were detected
by Western blot and ELISA assays. The expression and
secretion of MMP2 and MMP9 were significantly reduced
in the As-miR-221/222 group but were up-regulated in the
miR-221/222 group (Figure 2C). Therefore, miR-221 and
miR-222 are required for glioma cell invasion.
TIMP3 is a direct target of miR-221 and miR-222
To determine the mechanism of action of miR-221 and
miR-222 in glioma cell invasion, we performed a miRNA
target search using TargetScan and found that the “seed
sequence” of miR-221 and miR-222 matched the 3′ UTR
of the TIMP3 gene (Figure 3A), which has been evidenced
in non small cell lung cancer cells.[12] To detect whether
TIMP3 is indeed regulated by miR-221 and miR-222 in
glioma cells, we knocked-down miR-221/222 and ectopi-
cally expressed miR-221/222 in U251 and LN229 cells.
Western blot analysis showed that TIMP3 expression was
up-regulated in cells with reduced levels of miR-221/222,
whereas TIMP3 expression was down-regulated in cells
over-expressing miR-221/222 (Figure 3B). In addition, we
created pGL3-WT-TIMP3-3′UTR plasmids. Reporter
assays revealed that a reduction of miR-221/222 triggered
a marked increase of luciferase activity from pGL3-WT-Figure 3 TIMP3 is a target for miR-221 and miR-222. (A) Schematic rep
miR-221 and miR-222 (the seed sequence (AGCUACAU) was identical, as sh
and TIMP3 protein levels were detected by western blot assays. β-actin pro
constructs were transfected into cells that were then treated with As-miR-2
transfection. The ratio of normalized sensor to control luciferase activity is s
three independent experiments. * P <0.05 compared with control group, *TIMP3-3′UTR (Figure 3C). These data indicate that miR-
221/222 can directly modulate TIMP3 expression by bind-
ing to the 3′ UTR of TIMP3 in gliomas.
Expression of TIMP3 overrides miR-221/222-induced
invasion
Having demonstrated TIMP3 to be a direct target of miR-
221/222 by our present and other previous studies [12], the
importance of TIMP3 in miR-221/222-mediated cell inva-
sion is still unclear. We next introduced TIMP3 lacking its
3′ UTR into U251 and LN229 cells. Transwell and wound
healing assays showed that cells transfected with TIMP3
had significantly reduced cell invasion and migration. How-
ever, expression of TIMP3 largely abrogated the effects of
miR-221/222 on cell invasion (Figure 4A and B). Moreover,
similar trends were observed in the expression of proteins
relevant to invasion (TIMP3, MMP2 and MMP9)
(Figure 4C). These results indicate that TIMP3 is a major
target of miR-221 and miR-222 in regulating glioma cell
invasion.
As-miR-221/222 inhibits glioblastoma xenograft growth
and induces TIMP3 up-regulation
Because the levels of miR-221 and miR-222 are frequently
elevated in glioblastoma and because they play an important
role in cell survival, we further examined the effects of miR-resentation of the putative binding sites in the TIMP3 mRNA 3' UTR for
own). (B) Cells were transfected with As-miR-221/222 or miR-221/222
tein was assayed as a control. (C) pGL3-TIMP3-3'UTR luciferase
21 and/or As-miR-222. Luciferase activity was determined 48 h after
hown. Error bars represent standard deviation and were obtained from
* P <0.01 compared with control group.
Figure 4 Expression of TIMP3 abrogates miR-221/222-mediated invasion. (A) and (B) Cells were transfected with pcDNA-TIMP3 and miR-
221/222, and transwell assays (A) and wound healing assays (B) were performed. (C) Cells were transfected with pcDNA-TIMP3 lacking the 3’ UTR
and miR-221/222 and TIMP3, MMP2 and MMP9 protein levels were detected by western blot assays. β-actin protein was assayed as a control. In
addition, the levels of MMP2 and MMP9 were measured by ELISA assays. Error bars represent standard deviation and were obtained from three
independent experiments. ** P <0.01 compared with control group.
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model. Reduction of miR-221/222 levels inhibited tumor
growth in vivo, and over-expression of miR-221/222 slightlyincreased tumor growth (Figure 5A). Immunohistochemis-
try then revealed that TIMP3 levels were up-regulated in
As-miR-221/222 treated tumors and down-regulated in
Figure 5 Effects of miR-221/222 on tumor growth in a xenograft mouse model. (A) After establishment of subcutaneous tumors, As-miR-
221/222 and miR-221/222 were injected in a multi-site injection manner every 3 days for 15 days. Tumor volumes were measured every 2 days
during treatment. (B) Expression of TIMP3, MMP2 and MMP9 was detected by immunohistochemistry in xenograft tumor sections.
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and MMP-9 expression in xenograft tumor sections con-
firmed the in vitro data (Figure 5B). Thus, As-miR-221/222
could be a therapeutic target for glioma intervention.
Inverse correlation of expression of miR-221/222 and
TIMP3 in glioma tissues
Having demonstrated TIMP3 as a major target of miR-
221/222, we further investigated the correlation of be-
tween miR-221/222 and TIMP3 expression in gliomas.
We examined 50 human paraffin-embedded glioma spe-
cimens with complete clinical data by miRNA-LNA in
situ hybridization. Representative images of miR-221/222
are shown in Figure 6A. According to the expression
profile of miR-221/222 and TIMP3, the tissue samples
were categorized as low positive (≤3) and high positive
(>3). There was an inverse relationship between miR-
221/222 and TIMP3 levels in glioma tissues.
Significant prognostic value of miR-221/222 in high-grade
glioma
Our present data and previous studies have shown that
miR-221/222 affects the behavior of glioma cells including
invasion, proliferation, apoptosis and radioresistance, by
regulating multiple targets, including TIMP3, p27, PUMA,
and PTEN [13-15]. Thus, we reasoned that miR-221/222should have a critical prognostic value for glioma patients
(Figure 6B). We analyzed the overall survival of patients
and found significant differences between the low positive
group and the high positive group in high-grade gliomas.
Kaplan-Meier survival curve analysis showed that a highly
statistically significant correlation was observed between
the overall survival and the expression levels of miR-221
(P= 0.011) and miR-222 (P= 0.020) in high-grade gliomas
(Figure 6C). These data indicate that the miR-221/222
high positive cases have a markedly worse outcome.Discussion
Glioma cell invasion along white matter tracts is believed
to be one of the major reasons for the resistance to treat-
ment. A quantitative analysis of glioma cell invasion
would be of value for clinical applications and experi-
mental studies. However, in clinical studies, measure-
ments of tumor cell invasion remain controversial. DTI
is a new MRI technique that can reveal abnormalities
and destruction of white matter fibers and has been used
to measure the degree of white matter damage in brain
regions, thus providing the potential for quantitative ana-
lysis of tumor invasion [16]. Notably, we found that miR-
221 and miR-222 are associated with glioma cell invasion
by integrating expression and DTI data. In high-grade
glioma, DTI indicated a decrease and deflection of the
Figure 6 Clinical significance of miR-221/222 and TIMP3 expression in gliomas. (A) Expression of miR-221/222 and TIMP3 was analyzed in
representative of gliomas with LNA-ISH and immunohistochemical staining. Expression levels of miR-221/222 and TIMP3 were quantified as
described in methods. Heat map representing gene expression level is determined in a linear scale with a maximum value of 6 immunoreactive
score to highlight differences within this range. (B) Schematic representation summarizing data from the present study and earlier reports. MiR-
221/222 modulates glioma malignant phenotype by regulating multiple targets, indicating a critical prognostic value for glioma patients. (C)
Kaplan-Meier survival curves for miR-221 and miR-222 expression. High-grade glioma patients with high levels of miR-221 or miR-222 had a
significantly worse outcome. The expression level was categorized as low expression (final score ≤3) and high expression (>3). The number of
patients in each group was shown: miR-221, low expression (14 patients) and high expression (22 patients); miR-221, low expression (16 patients)
and high expression (20 patients).
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high levels of miR-221/222. To our knowledge, this is
the first report combining analysis of a glioma invasion
maker with DTI data.
MiR-221 and miR-222 share the same seed sequence,
which are short, evolutionarily conserved regions
through which miRNAs bind their target sites in mRNA
3' UTRs, indicating an important role in coordinated
regulation and function. Several genes have been found
to be common targets of these two miRNAs, such as
p27, Bmf and PTEN [13,17,18]. Our recent data have
shown that miR-221/222 inhibit cell apoptosis in human
glioma cells by targeting the proapoptotic gene, PUMA.
[14] Here, we demonstrated that miR-221/222 play an
important role in the regulation of glioma invasion bydirectly targeting TIMP3, an inhibitor of MMPs. Among
the MMPs, attention in human gliomas has focused on
gelatinases (MMP2 and MMP9) [19]. A major mechan-
ism for controlling the activity of MMPs in the pericellu-
lar space is mediated by the action of tissue inhibitors of
metalloproteinases (TIMPs), which bind to active MMPs
[20]. There are four metalloproteinase family members:
TIMP1, TIMP2, TIMP3 and TIMP4. TIMP3 is unique
within the TIMP family as it remains closely associated
to the extracellular matrix after being secreted by the cell
[21]. In our study, down-regulation of TIMP3 correlated
with increasing malignancy in human gliomas. TIMP3
was also inversely correlated with miR-221/222 expres-
sion. Ectopic expression of TIMP3 inhibited U251 and
LN229 glioma cell invasion through the inhibition of
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expression of TIMP3 could largely override miR-221/
222-mediated invasion. These results demonstrate that
TIMP3 is a core target of miR-221/222 in glioma cell
invasion.
The significance of miRNAs in prognostic determin-
ation has been shown in a variety of human cancers,
such as lung cancer, pancreatic cancer, neuroblastomas
and colon cancers [22-25]. However, few studies addres-
sing the correlation between miRNA expression and gli-
oma patient survival have been reported. Zhi et al.
screened the expression profile of 200 miRNAs in a sam-
ple set consisting of 84 astrocytoma samples and 20 nor-
mal adjacent tissue samples and found that low level of
miR-181b or miR-106a, or high level of miR-21, was sig-
nificantly associated with poor patient survival [26]. An-
other study reported that the cumulative 5 year survival
rate of glioma patients was 51.54% in the low miR-182-
expression group, whereas it was only 7.23% in the high
miR-182-expression group. Moreover, multivariate Cox
regression analysis indicated that miR-182 expression
was an independent prognostic indicator for the survival
of glioma patients [27]. In this study, our data suggest
that a high miR-221/222 expression level is a valuable
marker for pathological diagnosis and prognosis predic-
tion in high-grade glioma; high miR-221/222 expression
levels were significantly associated with poor survival in
high-grade glioma patients as determined by Kaplan-Meier
analysis. However, recent data showed that miR-221 and
miR-222 were downregulated in GBM and neither prog-
nostic nor predictive associations were found for miR-
221or miR-222 [28]. Thus, these controversial data needs
to be further investigation.
Conclusions
In summary, our data demonstrate that miR-221/222
regulate glioma cell invasion by directly targeting TIMP3.
We also provide direct evidence that high levels of miR-
221/222 expression are significantly associated with poorer
overall survival. To conclude, our data suggest that miR-
221/222 could be intrinsic regulators of progression in
glioma cells and could be used as potential targets
and predictors of survival in this devastating disease.
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